Document Detail

Cysteamine-induced duodenal ulcer and acid secretion in the rat.
MedLine Citation:
PMID:  7444368     Owner:  NLM     Status:  MEDLINE    
Duodenal ulcers can be produced in rats within 24 h by a single subcutaneous administration of cysteamine. To determine the role of gastric acid secretion in the pathogenesis of these ulcers, secretory and pathoanatomic studies were performed in chronic fistula rats ater an ulcerogenic dose of cysteamine. A prolonged increase of acid secretion was seen after cysteamine, reaching fourfold the basal level after 5 h. The acid response lasted for 10 to 11 h. After vagotomy cysteamine-induced acid secretion was markedly reduced. Ulcer formation was prevented by vagotomy and by drainage of the gastric juice before it entered the duodenum. When a gastric acid output equivalent to that produced by the ulcerogenic dose of cysteamine was induced by repeated injections of pentagastrin, no mucosal changes were seen in the duodenum. These results indicate that, although some acid in the duodenum is required for ulcer formation, the hypersecretion of acid induced by cysteamine is not the only factor responsible for the development of duodenal ulcer.
P Kirkegaard; S S Poulsen; F B Loud; C Halse; J Christiansen
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Scandinavian journal of gastroenterology     Volume:  15     ISSN:  0036-5521     ISO Abbreviation:  Scand. J. Gastroenterol.     Publication Date:  1980  
Date Detail:
Created Date:  1981-02-26     Completed Date:  1981-02-26     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0060105     Medline TA:  Scand J Gastroenterol     Country:  NORWAY    
Other Details:
Languages:  eng     Pagination:  621-4     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cysteamine / pharmacology*
Duodenal Ulcer / chemically induced*
Gastric Acid / secretion*
Gastric Fistula / physiopathology
Intestinal Mucosa / pathology
Pentagastrin / pharmacology
Secretory Rate / drug effects
Reg. No./Substance:
5534-95-2/Pentagastrin; 60-23-1/Cysteamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Analysis of plasma bile acid profiles in patients with liver diseases associated with cholestasis.
Next Document:  Serum phospholipase A2 in human acute pancreatitis.